The treatment offered is part of an investigational international pilot study. This experimental treatment is not FDA approved.
TOL has shown promising results in various advanced cancers. Below are highlights from published case reports:
(Annals of Oncology Case Reports, 2025) A 66-year-old male with a 25-year history of multiple SCCs underwent TOL at CORE. Pre-treatment biopsy confirmed VGSC overexpression. Treatment: Daily imiquimod + digoxin (0.25 mg) for 5 days, followed by pulsed electric field (PEF) sessions (45 min Day 1, 2 hours Day 2, repeated cycles).
Outcome:
Erythematous patches resolved; post-treatment biopsy showed minimal VGSC-expressing cells. No adverse effects; reduced need for Mohs surgery. Complete resolution of lesions without scarring. (Include figures from PDF if available: Pre/post photos, immunohistofluorescence.)
(Annals of Oncology Case Reports, 2025) A 51-year-old male with Stage 3 melanoma (2.1 mm ulcerated mass) refused Mohs surgery and chose TOL. Biopsy confirmed VGSC overexpression. Treatment: 3 cycles of digoxin loading + 2-hour PEF on consecutive days.
Outcome:
Complete resolution of primary lesion without scarring. MRI showed no residual tumor or metastases. No adverse effects; improved quality of life. (Include figures: Pre-treatment mass, VGSC labeling.)